Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is the first for schizophrenia in several decades. Cobenfy targets cholinergic receptors instead of balancing levels of dopamine and serotonin, which is what conventional atypical antipsychotics
Read More
Boeing faces new FAA review as key supplier plans temporary furloughs
Boeing’s biggest supplier of airplane parts says it will temporarily furlough 700 workers because of a slowdown in work
November 16, 2024
No Comments
